{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:00:29Z","timestamp":1791896429249,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.amjmed.2009.03.030","type":"journal-article","created":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T04:16:31Z","timestamp":1250741791000},"page":"962.e1-962.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review"],"prefix":"10.1016","volume":"122","author":[{"given":"Samuel","family":"Abourbih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto L.","family":"Schiffrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Rinfret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Pilote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2009.03.030_bib1","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.03.030_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.03.030_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0021-9150(00)00379-8","article-title":"Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)","volume":"150","author":"Pauciullo","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjmed.2009.03.030_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/diacare.21.4.641","article-title":"Cardiovascular outcomes in type 2 diabetes","volume":"21","author":"Elkeles","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.03.030_bib5","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.03.030_bib6","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/01.CIR.0000057982.50167.6E","article-title":"Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"107","author":"Vakkilainen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.03.030_bib7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ahj.2006.10.031","article-title":"Efficacy and safety of the coadministration of ezetimibe\/simvastatin with fenofibrate in patients with mixed hyperlipidemia","volume":"153","author":"Farnier","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2009.03.030_bib8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/eurheartj\/ehi231","article-title":"Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia","volume":"26","author":"Farnier","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2009.03.030_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0002-9343(87)90871-0","article-title":"Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia","volume":"83","author":"Knopp","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2009.03.030_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/clc.4960290609","article-title":"Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects","volume":"29","author":"Davidson","year":"2006","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjmed.2009.03.030_bib11","first-page":"184","article-title":"Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia","volume":"26","author":"Krempf","year":"2000","journal-title":"Diabetes Metab"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2009.03.030_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000174544","article-title":"Fenofibrate in type IV and type V hyperlipoproteinemia","volume":"76","author":"Seidehamel","year":"1989","journal-title":"Cardiology"},{"key":"10.1016\/j.amjmed.2009.03.030_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/07853899309147855","article-title":"Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease","volume":"25","author":"Frick","year":"1993","journal-title":"Ann Med"},{"key":"10.1016\/j.amjmed.2009.03.030_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2337\/diacare.16.1.37","article-title":"Effects of gemfibrozil on triglyceride levels in patients with NIDDM","volume":"16","author":"Vinik","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.03.030_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0021-9150(96)05941-2","article-title":"Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels","volume":"127","author":"Schaefer","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjmed.2009.03.030_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s005920050141","article-title":"The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients","volume":"36","author":"Avogaro","year":"1999","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.amjmed.2009.03.030_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0002-9343(93)90114-5","article-title":"Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia","volume":"94","author":"Wiklund","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2009.03.030_bib18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"New Engl J Med"},{"key":"10.1016\/j.amjmed.2009.03.030_bib19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2009.03.030_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.03.030_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ahj.2005.04.003","article-title":"Are statins created equal?","volume":"151","author":"Zhou","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2009.03.030_bib22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2796.2000.00646.x","article-title":"Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety","volume":"247","author":"Gavish","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjmed.2009.03.030_bib23","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.03.030_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.977","article-title":"Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy","volume":"13","author":"Chang","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.amjmed.2009.03.030_bib25","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00007611-200194100-00017","article-title":"Fatal rhabdomyolysis caused by lipid-lowering therapy","volume":"94","author":"Federman","year":"2001","journal-title":"South Med J"},{"key":"10.1016\/j.amjmed.2009.03.030_bib26","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jclinepi.2006.11.006","article-title":"Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population","volume":"60","author":"McClure","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjmed.2009.03.030_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000047304","article-title":"Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations","volume":"94","author":"Oldemeyer","year":"2000","journal-title":"Cardiology"},{"key":"10.1016\/j.amjmed.2009.03.030_bib28","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2009.03.030_bib29","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.03.030_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/01.ATV.12.2.187","article-title":"Low density lipoprotein particle size and coronary artery disease","volume":"12","author":"Campos","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.amjmed.2009.03.030_bib31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy","volume":"35","author":"Shek","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2009.03.030_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.amjmed.2009.03.030_bib33","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jama.1996.03540110036029","article-title":"A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction","volume":"276","author":"Stampfer","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.03.030_bib34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.03.030_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2009.03.030_bib36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archinte.165.7.725","article-title":"Effect of different antilipidemic agents and diets on mortality: a systematic review","volume":"165","author":"Studer","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2009.03.030_bib37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1185\/030079906X89865","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials","volume":"22","author":"Allemann","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjmed.2009.03.030_bib38","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jama.297.12.1362","article-title":"Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials","volume":"297","author":"Nissen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.03.030_bib39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934309004902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934309004902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:51:07Z","timestamp":1757580667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934309004902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0002934309004902"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2009.03.030","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2009.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}